- A new long-term pandemic preparedness agreement between CSL Seqirus and PAHO’s Regional Revolving Fund builds on the parties’ seasonal influenza collaboration to support rapid and scalable pandemic response.
- CSL Seqirus will leverage its global influenza manufacturing network and work with Sinergium Biotech to support regional fill-finish and distribution capabilities across Latin America and the Caribbean.
- Agreement reflects PAHO’s long-standing commitment to strengthening pandemic preparedness across its Member States in the face of emerging health threats.
BUENOS AIRES, ARGENTINA, May 12, 2026 – CSL Seqirus, a business of CSL (ASX: CSL), announced it has signed a new multi-year pandemic preparedness agreement with PAHO’s Regional Revolving Fund to help strengthen influenza pandemic preparedness across Latin America and the Caribbean.
Under the terms of the agreement, millions of doses of pandemic influenza vaccine have been reserved with CSL Seqirus and may be ordered by participating countries across Latin America and the Caribbean in the event of an influenza pandemic. The agreement requires CSL Seqirus to be prepared to rapidly manufacture and deliver these doses to help protect against the influenza strain identified by the World Health Organization (WHO) when an influenza pandemic is declared.
“A pandemic doesn’t wait for us to be ready. That’s exactly why agreements like this one matter,” said Gonzalo Pereira, Latin America General Manager, CSL Seqirus. "By reserving doses and embedding regional manufacturing capabilities, this agreement helps strengthen regional coordination and access to pandemic vaccines across Latin America and the Caribbean when the next influenza pandemic strikes."
This agreement builds on the parties’ multi-year collaboration for seasonal influenza vaccine supply in the region. CSL Seqirus will work with long-term production partner Sinergium Biotech, a leading Argentine vaccine company with industrial and regulatory capabilities at its plant in Garín, Buenos Aires Province, to support regional vaccine fill-finish and distribution.
Seasonal vaccine production creates an essential “warm base,” ensuring staff, production lines and key manufacturing components are ready to pivot to pandemic vaccine production in the event an influenza pandemic is declared. This warm base is key to enabling the speed and scale needed in a pandemic response.
Together, the seasonal and pandemic components of the partnership between CSL Seqirus and PAHO provide an important preparedness blueprint for the region; supporting routine influenza prevention today while helping establish the infrastructure, partnerships and manufacturing readiness needed for a future pandemic response.
Pandemic Preparedness in Latin America and the Caribbean
According to PAHO, future pandemics caused by influenza with epidemic and pandemic potential are highly likely.1 Given this threat, PAHO has stated it is a priority for governments across Latin America and the Caribbean to strengthen regional coordination and preparedness to manage future pandemic risk at short notice.1
"This agreement puts pandemic preparedness best practices into action, bringing together reserved doses, regional manufacturing capability, and a long-term public-private commitment,” said Dave Ross, Executive Vice President and General Manager, CSL Seqirus. “We're proud to establish this kind of partnership in Latin America and the Caribbean for the first time."
Across CSL Seqirus’ 30 plus government partnerships globally, this is the first agreement of its kind established in the region and is in addition to CSL Seqirus’ long-term commitment to the WHO to supply 10% of real-time production to developing countries in the event of a declared influenza pandemic.
About Pandemic Influenza
Influenza is a contagious airborne respiratory disease.2,3 The risk of influenza-associated morbidity and mortality is greater with pandemic influenza than with seasonal influenza because there is likely to be little or no pre-existing immunity to the novel virus in the human population.4 The timing and severity of pandemic influenza is unpredictable. Four influenza pandemics have occurred since 1918, with the 1918 pandemic being the most severe in recent history, with an estimated mortality of up to 50 million people worldwide.5
About CSL Seqirus
CSL Seqirus is part of CSL (ASX:CSL). As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.
For more information about CSL Seqirus, visit CSL.com.
About Sinergium Biotech
Sinergium Biotech is a leading Argentine pharmaceutical company, recognized as a reference in the development, production, and commercialization of highly complex vaccines and biotechnological medicines in the region. Committed to the highest international standards, Sinergium Biotech operates under Good Manufacturing Practices (GMP) and strictly complies with regulations set by the National Administration of Drugs, Food and Medical Technology (ANMAT), in line with Mercosur regulations.
For more information about Sinergium, visit www.sinergiumbiotech.com/en.
Intended Audience
This press release is issued from CSL Seqirus in Summit, New Jersey, USA and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved CSL Seqirus products may vary from country to country. Please consult your local regulatory authority on the approval status of CSL Seqirus products.
Forward-Looking Statements
This press release may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
MEDIA CONTACT
CSL Seqirus
Melanie Kerin
+44 7345 433260
Melanie.Kerin@Seqirus.com
GL-NOPR-26-0004
1 Pan American Health Organization. Framework of a national program for preventing and controlling diseases caused by respiratory viruses with epidemic and pandemic potential. Retrieved from: https://iris.paho.org/items/bf469776-c8ef-4950-be2a-5040b3f40810. Accessed May 2026.
2 U.S. Centers of Disease Control and Prevention (CDC). About Flu. Retrieved from: https://www.cdc.gov/flu/about/index.html. Accessed May 2026.
3 CDC. Key Facts About Seasonal Flu Vaccine. Retrieved from: https://www.cdc.gov/flu/vaccines/keyfacts.html. Accessed May 2026.
4 World Health Organization (WHO). How pandemic influenza emerges. Retrieved from: https://www.who.int/europe/news-room/fact-sheets/item/how-pandemic-influenza-emerges. Accessed May 2026.
5 WHO. Pandemic Influenza Risk Management: A WHO guide to inform and harmonize national and international pandemic preparedness and response. Retrieved from: https://apps.who.int/iris/bitstream/handle/10665/259893/WHO-WHE-IHM-GIP-2017.1-eng.pdf;jsessionid=4421F16879D2F8B96481F8D0C745C7F3?sequence=1. Accessed May 2026.